There is increasing evidence of discordance in estrogen receptor (ER, ESR), progesterone receptor (PGR) and human epidermal growth factor 2 (HER2/neu) status between primary breast tumors and metastatic and recurrent breast cancers, potentially impacting treatment options and ultimately affecting survival [85,86,87]. Here, PGR is linked to breast carcinoma.